Singapore markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
13.44+0.04 (+0.30%)
At close: 04:00PM EDT
13.36 -0.08 (-0.60%)
After hours: 06:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.40
Bid13.20 x 3200
Ask13.50 x 4000
Day's range13.38 - 13.50
52-week range12.58 - 16.39
Avg. volume1,492,751
Market cap43.013B
Beta (5Y monthly)0.50
PE ratio (TTM)48.00
Earnings dateN/A
Forward dividend & yield0.58 (4.35%)
Ex-dividend date27 Mar 2024
1y target estN/A
  • Zacks

    FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

    Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.

  • Zacks

    OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

    Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.

  • Benzinga

    Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%

    On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y. Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen. Takeda said it will incur restructuring costs of about 140 billion yen in fiscal year 2024 as part of a plan to optimize its workforce, cut costs, and strengthen technology. Revenue was 4.26 trillio